Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ferrara

Showing results (191-200 of 201) with videos related to

Pageof 21
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 28, 2011
Dermoscopy of scalp tumours: a multi-centre study conducted by the international dermoscopy societyI Stanganelli, G Argenziano, F Sera, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Molecular Ecology Resources|May 14, 2011
Permanent Genetic Resources added to Molecular Ecology Resources Database 1 December 2009-31 January 2010, Cynthia M Anderson, Gallego J Aparicio, et al.
The European Physical Journal. C, Particles and Fields|March 16, 2019
The cosmic ray shadow of the Moon observed with the ANTARES neutrino telescopeA Albert, M André, M Anghinolfi, et al.
Pageof 21

Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2019
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudesA Cortellini, A Leonetti, A Catino, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 28, 2011
Dermoscopy of scalp tumours: a multi-centre study conducted by the international dermoscopy societyI Stanganelli, G Argenziano, F Sera, et al.
Journal for Immunotherapy of Cancer|October 20, 2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validationAlessio Cortellini, Biagio Ricciuti, Marcello Tiseo, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Journal for Immunotherapy of Cancer|April 8, 2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapyAlessio Cortellini, Massimo Di Maio, Olga Nigro, et al.
European Journal of Cancer (Oxford, England : 1990)|May 2, 2021
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapySebastiano Buti, Melissa Bersanelli, Fabiana Perrone, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 2020
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50Alessio Cortellini, Marcello Tiseo, Giuseppe L Banna, et al.
Clinical Lung Cancer|July 19, 2020
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical OutcomesAlessio Cortellini, Alex Friedlaender, Giuseppe L Banna, et al.
Molecular Ecology Resources|May 14, 2011
Permanent Genetic Resources added to Molecular Ecology Resources Database 1 December 2009-31 January 2010, Cynthia M Anderson, Gallego J Aparicio, et al.
The European Physical Journal. C, Particles and Fields|March 16, 2019
The cosmic ray shadow of the Moon observed with the ANTARES neutrino telescopeA Albert, M André, M Anghinolfi, et al.
Pageof 21